1. Ireland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRVF
Nabriva Therapeutics plcUS flagOther OTC
0.00
USD
- -
- -
323.00Market Cap
Nabriva Therapeutics plc
NBRVF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
31.99
26.11
5.57
15.7
13.3
9.62
Revenue per Share
142.25
-130.7
-22.19
-638.9
-623.15
-564.91
-278.86
-135.23
-28.52
-21.32
-18.02
Basic EPS, GAAP
-47.88
-105.66
-10.43
-569.51
-591.01
-359.05
-242.43
-139.05
-34.36
-13.77
-4.26
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1,055.77
-1,079.24
-79.85
-2,350.09
-2,336.79
-1,935.73
-1,605.97
-1,062.69
-343.52
-243.41
-220.49
Book Value per Share
-213.83
-337.14
51.35
896.09
686.34
337.29
138.76
64.33
30.75
1.23
-5.34
Tangible Book Value per Share
- -
- -
2
- -
- -
- -
- -
1
2
3
3
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
6
8
3
27
36
29
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-1,759.62
-1,025.93
-2,308.87
-178.31
-143.47
-169.17
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
1
- -
- -
Depreciation Expense
15
-14
-47
-55
-74
-115
-83
-69
-49
-57
-55
Net Income, GAAP
6.47
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-1,765.85
-1,068.2
-2,426.12
-181.69
-160.33
-187.34
Profit Margin (%)
-14
-31
107
75
81
91
75
39
58
3
-16
Working Capital
1
3
- -
- -
- -
24
35
6
4
- -
- -
LT Debt
-23
-37
109
77
82
69
41
33
53
3
-16
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
5
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
31
24
10
Cash, Cash Equivalents & STI
12
2
2
Accounts Receivable, Net
6
11
4
Inventories
10
9
- -
Total Current Liabilities
28
28
26
Payables & Accruals
21
27
25
ST Debt
5
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-21.75%
-93.83%
Free Cash Flow
- -
-10.65%
-38.03%
Net Income, GAAP
- -
-0.55%
15.64%
Sales/Revenue/Turnover
- -
- -
31.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
2
8
8
9
27
2022
8
9
9
10
36
2023
8
3
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-13.23
-7.24
-5.27
-5.89
-28.52
2022
-5.03
-4.38
-4.21
- -
-21.32
2023
-2.72
-3.73
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
CSPC Pharmaceutical Group Limited (CSPCY)
Diagnamed Holdings Corp. (DMED.CN)
Inventiva S.A. (0RNK.L)
VectivBio Holding AG (VECT)
SillaJen, Inc. (215600.KQ)
EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
Business
Nabriva Therapeutics plc is a biopharmaceutical company specializing in the development and commercialization of anti-infective agents for the treatment of serious infections. Its core product portfolio includes novel antibiotics such as lefamulin, marketed under the brand name Xenleta, which is approved for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. The company focuses on innovative therapeutic solutions addressing multidrug-resistant bacterial pathogens. Nabriva operates primarily in North America and Europe, targeting healthcare providers and medical institutions. Founded in 2006, the company is headquartered in Dublin, Ireland, and has development and commercialization activities in various international markets. Nabriva pursues strategic partnerships and collaborations to expand its product pipeline and market reach. In recent major developments, Nabriva has advanced its clinical pipeline with new product formulations and delivery methods, and it has entered into strategic collaborations to enhance commercialization and distribution efforts. The company has strengthened its position through business expansions aimed at addressing urgent medical needs related to antimicrobial resistance. These strategic moves illustrate Nabriva's commitment to innovation and growth within the pharmaceutical industry.